Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness

British Journal of Ophthalmology

Volumn 91, Issue 9, 2007, Pages 1244-1246

  Raftery, James ^a   Clegg, Andrew ^a   Jones, Jeremy ^a   Seng, Chuen Tan ^a   Lotery, Andrew ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EYE DISEASE; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MACULAR DEGENERATION; MARKOV CHAINS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 34548324016     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.116616     Document Type: Short Survey

References (19)

1. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355(14): 1409-12.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-44.
3. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Arch Ophthalmol 2002;120(11):1443-54.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31.
5. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108(11):2051-9.
6. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004;88(9):1107-12.
7. Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118(1):47- 51.
8. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7(9):98.
9. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87(10):1201-4.
10. Government Actuary's Department. UK Interim Life Tables 2002-2004. London: GAD, 2005.
11. Zhou S, Javitt J, Zlateva G, et al. Evaluating the risk of mortality for exudative (wet) AMD patients compared to a control group. Invest Ophthalmol Vis Sci 2006;47:E-Abstract, 2213.
12. Department of Health. NHS Reference Cost 2005. London: Department of Health, 2006, Available from http://www.dh.gov.uk/PublicationsAndStatistics/ Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/ fs/en?CONTENT_ID=4133221&chk=TxHkqo (accessed 29 June 2007).
13. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26(3): 352-4.
14. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363-72.
15. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26(3):279-84.
16. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37(2):144-6.
17. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26(4):383-90.
18. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26(3):275-8.
19. Fung AE, Rosenfeld PJ, Reichel EZ. Intravitreal Avastin safety survey: results from the world wide web. Invest Ophthalmol Vis Sci 2006;47(5):5251.